Concord Drugs (BOM:538965) Cyclically Adjusted Revenue per Share: ₹78.09 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:538965 Concord Drugs Ltd BOM:538965
64 GF Score
Price ₹81.92
GF Value ₹64.34
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Concord Drugs Cyclically Adjusted Revenue per Share?

Concord Drugs BOM:538965 +1.61% 64 Cyclically Adjusted Revenue per Share is ₹78.09 as of Jun. 2026. GuruFocus rates BOM:538965 with a GF Score™ of 64/100 and a GF Value™ of ₹64.34 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Concord Drugs's adjusted revenue per share for the three months ended in Jun. 2026 was ₹15.976. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹78.09 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Concord Drugs's average Cyclically Adjusted Revenue Growth Rate was -0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-02), Concord Drugs's current stock price is ₹81.92. Concord Drugs's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹78.09. Concord Drugs's Cyclically Adjusted PS Ratio of today is 1.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Concord Drugs was 1.11. The lowest was 0.38. And the median was 0.51.


Concord Drugs  (BOM:538965) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Concord Drugs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=81.92/78.09
=1.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Concord Drugs was 1.11. The lowest was 0.38. And the median was 0.51.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Concord Drugs Cyclically Adjusted Revenue per Share Related Terms


Concord Drugs Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Concord Drugs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs Cyclically Adjusted Revenue per Share Chart

Concord Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 78.84 78.83 77.93

Concord Drugs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.73 78.37 77.20 77.93 78.09

BOM:538965 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Concord Drugs's Cyclically Adjusted PS Ratio falls into.


BOM:538965
64GF Score
Concord Drugs Ltd BOM:538965
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Drugs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Concord Drugs's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.976/167.3573*167.3573
=15.976

Current CPI (Jun. 2026) = 167.3573.

Concord Drugs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 19.224 105.961 30.363
201612 12.738 105.196 20.265
201703 29.556 105.196 47.021
201706 28.953 107.109 45.239
201709 5.108 109.021 7.841
201712 6.860 109.404 10.494
201803 26.832 109.786 40.902
201806 16.314 111.317 24.527
201809 15.403 115.142 22.388
201812 12.514 115.142 18.189
201903 17.547 118.202 24.844
201906 14.867 120.880 20.583
201909 14.967 123.175 20.336
201912 12.309 126.235 16.319
202003 14.715 124.705 19.748
202006 20.911 127.000 27.556
202009 18.897 130.118 24.305
202012 9.436 130.889 12.065
202103 9.545 131.771 12.123
202106 23.227 134.084 28.991
202109 11.161 135.847 13.750
202112 15.311 138.161 18.547
202203 17.749 138.822 21.397
202206 14.042 142.347 16.509
202209 15.887 144.661 18.380
202212 15.483 145.763 17.777
202303 11.188 146.865 12.749
202306 9.705 150.280 10.808
202309 8.028 151.492 8.869
202312 12.720 152.924 13.921
202403 15.718 153.035 17.189
202406 12.849 155.789 13.803
202409 11.392 157.882 12.076
202412 10.956 158.323 11.581
202503 10.658 157.552 11.321
202506 13.873 159.755 14.533
202509 10.148 162.289 10.465
202512 12.516 163.281 12.828
202603 33.726 164.272 34.359
202606 15.976 167.357 15.976

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹78.09 mean?
Concord Drugs (BOM:538965) has a Cyclically Adjusted Revenue per Share of ₹78.09 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Concord Drugs and its competitors.
Is Concord Drugs' Cyclically Adjusted Revenue per Share too high?
Concord Drugs' current Cyclically Adjusted Revenue per Share is ₹78.09. Overall, Concord Drugs has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Cyclically Adjusted Revenue per Share compare to ZTS?
Concord Drugs' Cyclically Adjusted Revenue per Share of ₹78.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Concord Drugs and its competitors. Concord Drugs's current Cyclically Adjusted Revenue per Share is ₹78.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹64.34, compared to a current price of ₹81.92 — trading 27.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹78.09. Concord Drugs' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Cyclically Adjusted Revenue per Share is ₹78.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹81.92 is trading 27.3% above its estimated GF Value™ of ₹64.34. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • Cyclically Adjusted Revenue per Share: ₹78.09
  • GF Value™: ₹64.34 vs. price of ₹81.92 (27.3% above fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
64GF Score

Get the complete analysis for BOM:538965

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹81.92
Price
₹64.34
GF Value